How to buy Arcus Biosciences stock (RCUS)

Arcus Biosciences is a biotechnology business based in the US. Arcus Biosciences shares (RCUS) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $15.50 – a decrease of 3.61% over the previous week. Arcus Biosciences employs 577 staff and has a trailing 12-month revenue of around $263 million.

Our top picks for where to buy Arcus Biosciences stock

Buy Arcus Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Arcus Biosciences stock price (NYSE: RCUS)

Use our graph to track the performance of RCUS stocks over time.

Arcus Biosciences shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$15.50
52-week range	$13.52 - $20.31
50-day moving average more info button	$16.52
200-day moving average more info button	$16.28
Wall St. target price	$33.20
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.19

Is it a good time to buy Arcus Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcus Biosciences price performance over time

Historical closes compared with the close of $15.46 from 2024-12-19

1 week (2024-12-13)	-3.86%
1 month (2024-11-22)	5.17%
3 months (2024-09-20)	-6.19%
6 months (2024-06-21)	-5.44%

1 year (2023-12-22)	-14.82%
2 years (2022-12-22)	-27.69%
3 years (2021-12-22)	41.81
5 years (2019-12-20)	63.94%

Arcus Biosciences financials

Revenue TTM	$263 million
Gross profit TTM	$-176,000,000
Return on assets TTM	-15.25%
Return on equity TTM	-49.77%
Profit margin	-102.66%
Book value	$6.18
Market Capitalization more info button	$1.4 billion

TTM: trailing 12 months

Arcus Biosciences share dividends

We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.

Arcus Biosciences share price volatility

Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $13.52 up to $20.31. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 0.89. This would suggest that Arcus Biosciences's shares are less volatile than average (for this exchange).

Arcus Biosciences overview

Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L. P.

Frequently asked questions

null
What percentage of Arcus Biosciences is owned by insiders or institutions?
Currently 40.599% of Arcus Biosciences shares are held by insiders and 60.072% by institutions. How many people work for Arcus Biosciences?
Latest data suggests 577 work at Arcus Biosciences. When does the fiscal year end for Arcus Biosciences?
Arcus Biosciences's fiscal year ends in December. Where is Arcus Biosciences based?
Arcus Biosciences's address is: 3928 Point Eden Way, Hayward, CA, United States, 94545 What is Arcus Biosciences's ISIN number?
Arcus Biosciences's international securities identification number is: US03969F1093 What is Arcus Biosciences's CUSIP number?
Arcus Biosciences's Committee on Uniform Securities Identification Procedures number is: 03969F109